China SXT Pharmaceuticals, Inc.
SXTC
$0.09
-$0.01-5.62%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -253.06% | -551.47% | -6.62% | 114.46% | 140.99% |
| Total Depreciation and Amortization | -72.78% | -65.50% | -59.45% | -43.66% | -30.45% |
| Total Amortization of Deferred Charges | 156.77% | 106.68% | 77.87% | 30.14% | -28.89% |
| Total Other Non-Cash Items | 192.89% | 229.30% | 25.66% | -146.26% | -161.31% |
| Change in Net Operating Assets | 15.64% | -19.96% | -154.66% | -318.96% | -197.24% |
| Cash from Operations | -1.30% | -9.77% | -21.65% | -147.70% | -2,333.09% |
| Capital Expenditure | 71.43% | 71.43% | 71.43% | 84.38% | 86.17% |
| Sale of Property, Plant, and Equipment | -38.42% | 123.15% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6,800.00% | -2,058.90% | -- | -73.46% | -25.81% |
| Cash from Investing | -2,002.11% | -1,235.50% | 140.91% | 2,082.14% | 248.13% |
| Total Debt Issued | -92.96% | -18.96% | 413.79% | 190.96% | 110.68% |
| Total Debt Repaid | -493.40% | -10.21% | 52.19% | -272.77% | -86.31% |
| Issuance of Common Stock | -- | -- | -- | 25.75% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 62.02% | 29.68% | -22.46% | 42.24% | 58.78% |
| Cash from Financing | -28.01% | 131.50% | 420.04% | 152.34% | -4.97% |
| Foreign Exchange rate Adjustments | -132.62% | -102.99% | 91.48% | 133.57% | 168.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.91% | 397.37% | 214.38% | 310.30% | -16.93% |